Stryker Corporation (SYK) Holdings Reduced by Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P.
Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. decreased its holdings in shares of Stryker Corporation (NYSE:SYK) by 1.3% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,568 shares of the medical technology company’s stock after selling 210 shares during the period. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P.’s holdings in Stryker Corporation were worth $2,299,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Bollard Group LLC raised its position in Stryker Corporation by 0.4% during the 2nd quarter. Bollard Group LLC now owns 832 shares of the medical technology company’s stock valued at $115,000 after purchasing an additional 3 shares during the last quarter. Motco raised its position in Stryker Corporation by 50.7% during the 2nd quarter. Motco now owns 826 shares of the medical technology company’s stock valued at $115,000 after purchasing an additional 278 shares during the last quarter. James Investment Research Inc. bought a new position in Stryker Corporation during the 2nd quarter valued at approximately $155,000. Guardian Life Insurance Co. of America raised its position in Stryker Corporation by 0.8% during the 1st quarter. Guardian Life Insurance Co. of America now owns 1,199 shares of the medical technology company’s stock valued at $158,000 after purchasing an additional 9 shares during the last quarter. Finally, Assetmark Inc. raised its position in Stryker Corporation by 0.3% during the 1st quarter. Assetmark Inc. now owns 1,274 shares of the medical technology company’s stock valued at $168,000 after purchasing an additional 4 shares during the last quarter. 74.13% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Stryker Corporation (SYK) Holdings Reduced by Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P.” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.watchlistnews.com/stryker-corporation-syk-holdings-reduced-by-holt-capital-advisors-l-l-c-dba-holt-capital-partners-l-p/1616965.html.
In other news, insider David Floyd sold 19,305 shares of the business’s stock in a transaction on Wednesday, July 12th. The shares were sold at an average price of $144.56, for a total transaction of $2,790,730.80. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Graham A. Mclean sold 1,124 shares of the business’s stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $146.26, for a total transaction of $164,396.24. Following the sale, the insider now directly owns 8,983 shares in the company, valued at $1,313,853.58. The disclosure for this sale can be found here. Insiders sold 25,429 shares of company stock worth $3,686,927 over the last ninety days. Corporate insiders own 7.40% of the company’s stock.
SYK has been the topic of a number of research analyst reports. BidaskClub downgraded Stryker Corporation from a “strong-buy” rating to a “buy” rating in a report on Tuesday, June 13th. Cowen and Company reiterated a “buy” rating and set a $160.00 target price (up previously from $150.00) on shares of Stryker Corporation in a report on Sunday, July 30th. Stifel Nicolaus upped their target price on Stryker Corporation from $151.00 to $158.00 and gave the stock a “buy” rating in a report on Friday, July 28th. Zacks Investment Research upgraded Stryker Corporation from a “hold” rating to a “buy” rating and set a $163.00 target price on the stock in a report on Monday, July 17th. Finally, Canaccord Genuity reiterated a “buy” rating and set a $155.00 target price (down previously from $158.00) on shares of Stryker Corporation in a report on Thursday, August 24th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $146.78.
Shares of Stryker Corporation (NYSE SYK) opened at 149.00 on Friday. The firm’s 50-day moving average price is $142.44 and its 200 day moving average price is $139.99. The stock has a market capitalization of $55.74 billion, a P/E ratio of 33.26 and a beta of 0.80. Stryker Corporation has a 52 week low of $106.48 and a 52 week high of $149.23.
Stryker Corporation (NYSE:SYK) last released its quarterly earnings results on Thursday, July 27th. The medical technology company reported $1.53 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.51 by $0.02. Stryker Corporation had a net margin of 14.22% and a return on equity of 24.26%. The business had revenue of $3.01 billion for the quarter, compared to analyst estimates of $2.98 billion. During the same period in the previous year, the company earned $1.39 earnings per share. The business’s revenue for the quarter was up 6.1% on a year-over-year basis. Analysts expect that Stryker Corporation will post $6.46 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, October 31st. Shareholders of record on Friday, September 29th will be issued a $0.425 dividend. This represents a $1.70 annualized dividend and a yield of 1.14%. The ex-dividend date of this dividend is Thursday, September 28th. Stryker Corporation’s dividend payout ratio is currently 37.95%.
Stryker Corporation Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK).
Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.